Form 4: BridgeBio CFO Sells Shares Under 10b5-1 Plan

BridgeBio Pharma's President and CFO, Thomas Trimarchi, reported the sale of common stock and shares withheld for tax obligations, reducing his direct beneficial ownership.

Summary

• Thomas Trimarchi, President and CFO of BridgeBio Pharma, Inc. (BBIO), reported changes in his beneficial ownership of common stock.
• On November 16, 2025, 21,317 shares of common stock were withheld to satisfy tax obligations related to the vesting of 38,547 Restricted Stock Units (RSUs). The shares were valued at $66.39 each.
• On November 17, 2025, Trimarchi sold 9,978 shares of common stock at a weighted average price of $66.1923 per share, with prices ranging from $65.575 to $66.57.
• Also on November 17, 2025, an additional 6,956 shares of common stock were sold at a weighted average price of $66.8398 per share, with prices ranging from $66.61 to $67.26.
• Both sales transactions on November 17, 2025, were executed pursuant to a Rule 10b5-1 sales plan adopted by Trimarchi on March 31, 2025.
• After these transactions, Trimarchi directly beneficially owns 382,830 shares of BridgeBio Pharma, Inc. common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including RSU vesting and pre-planned sales under a 10b5-1 plan. While insider selling can sometimes be perceived negatively, the pre-arranged nature mitigates concerns, making the overall sentiment neutral.

Positives

• The vesting of 38,547 Restricted Stock Units (RSUs) indicates compensation for the executive.
• The sales were conducted under a pre-arranged Rule 10b5-1 plan, which suggests the transactions were not based on new, non-public information.

Negatives

• The net effect of the transactions is a reduction in the insider's direct beneficial ownership of common stock by 38,251 shares (21,317 shares withheld for tax + 9,978 shares sold + 6,956 shares sold).

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor impact due to routine insider selling under a pre-arranged plan, which is a common practice for executive compensation and personal financial management.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, insider transaction, stock sale, executive compensation, Thomas Trimarchi, 10b5-1 plan, beneficial ownership, common stock, RSU vesting